Drugs / Staph aureus types 5 and 8 conjugate vaccine
Staph aureus types 5 and 8 conjugate vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00130260 | Aug → Dec 2005 | chronic renal failure syndrome, staphylococcal infection | Nabi Biopharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Staph aureus types 5 and 8 conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00130260 ↗ |
| Modality | Vaccine | “StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine” NCT00130260 ↗ |
| Route | Intramuscular | “each IM dose contains 200 mc total conjugate” NCT00130260 ↗ |